Fig. 2: Clinical characteristics of the two groups.
From: Enhanced inflammation and suppressed adaptive immunity in COVID-19 with prolonged RNA shedding
a, b Comparative quantification of six antibody categories between the LC and SC groups. Number of samples collected for each week: 10 SC and 8 LC in week 1, 16 SC and 13 LC in week 2, 16 SC and 13 LC in week 3, 11 SC and 15 LC in week 4, 13 SC and 9 LC in week 5, 10 SC and 11 LC in week 6, 8 SC and 5 LC in week 7, 9 SC and 9 LC in week 8, 8 LC in week 9; total samples: 93 from 17 SC patients, and 91 from 19 LC patients. The profiles of the serum anti-S, anti-RBD, and anti-N IgM (a) and IgG (b) between the two groups along time. Orange asterisks mean significant variance over 8–9 time points in the SC group (one-way ANOVA). Purple asterisk means significant variance over 8–9 time points in the LC group (one-way ANOVA). Black asterisks show the interactional difference between time points and LC/SC group (two-way ANOVA). *P < 0.05; **P < 0.01; ***P < 0.001. c Flow cytometry analysis of immune cells between the SC and LC patients. 22 samples from 17 LC patients and 30 samples from 17 SC patients were analyzed. Flow cytometry analysis of lymphocytes, CD4+ cells and CD127–CD25+ Treg cells of two representative patients (P-value from Welch’s t-test). The bean plots show the comparison between the two groups.
